P J Kanki

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Scaling up HIV treatment and prevention through national responses and innovative leadership
    Phyllis Kanki
    Department of Immunology and Infectious Disease, Harvard School of Public Health, Boston, MA 02115, USA
    J Acquir Immune Defic Syndr 60:S27-30. 2012
  2. ncbi Human immunodeficiency virus type 1 subtypes differ in disease progression
    P J Kanki
    Department of Immunology, Harvard School of Public Health, Boston, Massachusetts, USA
    J Infect Dis 179:68-73. 1999
  3. ncbi Robust HIV type 2 cellular immune response measured by a modified anthrax toxin-based enzyme-linked immunospot assay
    A D Sarr
    Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    AIDS Res Hum Retroviruses 17:1257-64. 2001
  4. ncbi In vitro correlates of HIV-2-mediated HIV-1 protection
    E G Kokkotou
    Harvard AIDS Institute, Department of Immunology and Infectious Diseases, Harvard School of Public Health, 651 Huntington Avenue, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 97:6797-802. 2000
  5. ncbi Absence of antibodies to HIV-2/HTLV-4 in six central African nations
    P J Kanki
    Department of Cancer Biology, Harvard School of Public Health, Boston, MA
    AIDS Res Hum Retroviruses 3:317-22. 1987
  6. ncbi Regulation of adiponectin in adipocytes upon exposure to HIV-1
    J L G Sankalé
    Department of Immunology and Infectious Diseases and Harvard AIDS Institute, Harvard School of Public Health, Boston, MA, USA
    HIV Med 7:268-74. 2006

Research Grants

  1. HIV-2 CELLULAR IMMUNITY CROSS-REACTIVE WITH HIV-1
    Phyllis Kanki; Fiscal Year: 2003
  2. HIV-2--A MODEL OF HIV PRIMARY INFECTION
    Phyllis Kanki; Fiscal Year: 2002
  3. CORRELATES OF HIV-1 PROTECTION
    Phyllis Kanki; Fiscal Year: 2004

Collaborators

  • G S Hotamisligil
  • N Clumeck
  • P Hermans
  • J L G Sankalé
  • A D Sarr
  • S Mboup
  • E G Kokkotou
  • S K Grinspoon
  • G Tan
  • C M Hadigan
  • Q Tong
  • H Cao
  • S Popper
  • Y Lu
  • G Eisen
  • M E Essex
  • J L Sankale
  • D Schwartz
  • A Gueye-Ndiaye
  • I Mani

Detail Information

Publications6

  1. ncbi Scaling up HIV treatment and prevention through national responses and innovative leadership
    Phyllis Kanki
    Department of Immunology and Infectious Disease, Harvard School of Public Health, Boston, MA 02115, USA
    J Acquir Immune Defic Syndr 60:S27-30. 2012
    ..Examples from Brazil, Botswana, Nigeria, Uganda, and India illustrate the vital role played by bold and collaborative leadership in the global and local scale-up of HIV prevention and treatment...
  2. ncbi Human immunodeficiency virus type 1 subtypes differ in disease progression
    P J Kanki
    Department of Immunology, Harvard School of Public Health, Boston, Massachusetts, USA
    J Infect Dis 179:68-73. 1999
    ..23; P=. 009), the predominant subtype in the study. These data suggest that HIV-1 subtypes may differ in rates of progression to AIDS...
  3. ncbi Robust HIV type 2 cellular immune response measured by a modified anthrax toxin-based enzyme-linked immunospot assay
    A D Sarr
    Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    AIDS Res Hum Retroviruses 17:1257-64. 2001
    ..This simple and rapid modified anthrax toxin-based ELISPOT method allowed us to demonstrate, strong cellular immune responses that may be critical determinants in the HIV-2 attenuated phenotype...
  4. ncbi In vitro correlates of HIV-2-mediated HIV-1 protection
    E G Kokkotou
    Harvard AIDS Institute, Department of Immunology and Infectious Diseases, Harvard School of Public Health, 651 Huntington Avenue, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 97:6797-802. 2000
    ..Our results suggest that beta-chemokine-mediated resistance may be an important correlate of HIV protection against HIV-1 infection and relevant to HIV vaccine design...
  5. ncbi Absence of antibodies to HIV-2/HTLV-4 in six central African nations
    P J Kanki
    Department of Cancer Biology, Harvard School of Public Health, Boston, MA
    AIDS Res Hum Retroviruses 3:317-22. 1987
    ..These results indicate that HIV-2/HTLV-4 has a distinct geographic distribution from that of HIV-1 in Africa. Further studies are necessary to better define the pathogenicity and natural history of this distinct new virus, HIV-2/HTLV-4...
  6. ncbi Regulation of adiponectin in adipocytes upon exposure to HIV-1
    J L G Sankalé
    Department of Immunology and Infectious Diseases and Harvard AIDS Institute, Harvard School of Public Health, Boston, MA, USA
    HIV Med 7:268-74. 2006
    ..In this study we investigated the effect of HIV on adipocytes, to determine whether HIV can directly infect adipocytes and/or alter the regulation and secretion of the adipocyte-derived hormone adiponectin...

Research Grants12

  1. HIV-2 CELLULAR IMMUNITY CROSS-REACTIVE WITH HIV-1
    Phyllis Kanki; Fiscal Year: 2003
    ..Not only will these studies provide new information on the breadth and cross-reactivity of the HIV-2 cellular immune responses, but we also hope to correlate such responses with HIV-1 protection in vivo. ..
  2. HIV-2--A MODEL OF HIV PRIMARY INFECTION
    Phyllis Kanki; Fiscal Year: 2002
    ..The identification of temporal, qualitative, and quantitative aspects of these immune responses should contribute to out growing understanding of the determinants of HIV pathogenicity. ..
  3. CORRELATES OF HIV-1 PROTECTION
    Phyllis Kanki; Fiscal Year: 2004
    ..4. We will determine the profile of beta chemokine message and protein in the evaluated HIV-2 infected women and study the association of beta chemokines with in vivo protection from HIV-1 infection. ..